Welcome to our dedicated page for Arcturus Therapeutics Holdings news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therapeutics Holdings stock.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), founded in 2013 and based in San Diego, California, is a pioneering RNA medicines company focused on developing novel therapeutics for rare diseases, particularly those with no adequate treatments. Specializing in RNA interference (RNAi) technologies, Arcturus is at the forefront of creating breakthrough treatments aimed at liver and respiratory diseases.
Arcturus operates primarily in the research and development sector, focusing on nucleic acid-based medical applications. Core technologies include its proprietary LUNAR® lipid-mediated delivery and STARR® mRNA Technology (sa-mRNA), enabling a versatile range of RNA therapeutics. Its mRNA drug substance and product manufacturing expertise further position Arcturus as a leader in RNA-based solutions.
Key projects in Arcturus' pipeline include:
- LUNAR-OTC for treating ornithine transcarbamylase deficiency
- LUNAR-CF aimed at cystic fibrosis
- LUNAR-FLU and LUNAR-COV19 for influenza and COVID-19 vaccines respectively
Recently, Arcturus announced a collaborative research endeavor with PassPort Technologies Inc. (PPTI) to explore innovative mRNA formulations and transdermal delivery methods for vaccines and therapeutics. This partnership leverages ARCT’s LUNAR® platform and PPTI’s PassPort® transdermal technology, aiming to enhance the delivery and efficacy of RNA-based treatments.
Further cementing its competitive edge, Arcturus has developed Kostaive®, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine. Arcturus continues its global collaboration with CSL Seqirus for mRNA vaccines and maintains a joint venture in Japan, ARCALIS, to manufacture mRNA vaccines and therapeutics. The company’s extensive patent portfolio, covering over 400 patents across the U.S., Europe, Japan, China, and other countries, underscores its innovative prowess.
Financially, Arcturus maintains a solid growth trajectory, driven by its robust research initiatives and strategic alliances. For more detailed information, visit their official website at www.ArcturusRx.com, and connect via Twitter and LinkedIn.
Arcturus Therapeutics (Nasdaq: ARCT), a commercial mRNA vaccines and medicines company, announced it will release its Q3 2024 financial results on November 7, 2024, after market close. The company will also host a conference call and webcast at 4:30 pm ET on the same day to discuss the results and provide a corporate update. The call can be accessed domestically at 1-800-274-8461 and internationally at 1-203-518-9814 using the conference ID: ARCTURUS. A webcast link will be available for streaming.
CSL and Arcturus Therapeutics announced results from a head-to-head study showing their self-amplifying mRNA (sa-mRNA) COVID-19 vaccine ARCT-154 maintained superior immunogenicity compared to Comirnaty® for up to one year. The study, presented at the OPTIONS XII conference, demonstrated:
1. Higher antibody levels against multiple SARS-CoV-2 strains, including Wuhan-Hu-1 and Omicron variants.
2. Effectiveness at one-sixth the dose of Comirnaty® (5 μg vs 30 μg).
3. Superior durability of immune response in both younger and older adults.
Additionally, their bivalent vaccine ARCT-2301 showed superior immunogenicity over Comirnaty® bivalent vaccine up to six months post-vaccination. The sa-mRNA platform vaccine targeting the JN.1 variant is now approved in Japan under the name KOSTAIVE®.
CSL (CSLLY) and Arcturus Therapeutics announced results from a head-to-head study showing their self-amplifying mRNA (sa-mRNA) COVID-19 vaccine maintained superior immunogenicity compared to Comirnaty® for up to one year. The study, presented at the OPTIONS XII conference, demonstrated ARCT-154 elicited superior antibody persistence against multiple SARS-CoV-2 strains at one-sixth the dose of Comirnaty®.
Key findings include:
- ARCT-154 showed superior neutralizing antibodies against Wuhan-Hu-1 strain at Day 361
- Similar advantages were observed against Omicron BA.4-5 and other variants
- A bivalent formula, ARCT-2301, also demonstrated superior immunogenicity over Comirnaty®
The sa-mRNA COVID-19 vaccine is approved in Japan under the name KOSTAIVE® for adults 18 and older.
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics announced that Japan's Ministry of Health, Labor and Welfare has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®, for adults 18 and older. The vaccine is tailored to protect against the JN.1 lineage of Omicron subvariants. Meiji Seika Pharma, CSL's exclusive partner in Japan, will distribute the vaccine for the October COVID-19 vaccination campaign.
KOSTAIVE® is the world's first commercially available sa-mRNA COVID-19 vaccine. Clinical evidence supports its safety and effectiveness, with data showing superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA vaccines and immunity lasting up to one year. This approval aligns with recent World Health Organization recommendations and demonstrates CSL and Arcturus' commitment to innovative vaccine technology for viral respiratory diseases.
CSL and Arcturus Therapeutics announced that Japan's Ministry of Health, Labor and Welfare has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®, for adults 18 and older. The vaccine is tailored to protect against the JN.1 lineage of Omicron subvariants. Meiji Seika Pharma, CSL's exclusive partner in Japan, will distribute the vaccine for the October 2024 vaccination campaign.
KOSTAIVE® is the world's first commercially available sa-mRNA COVID-19 vaccine for adults. Clinical data showed superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA vaccines and immunity lasting up to one year. This approval aligns with recent World Health Organization recommendations and demonstrates CSL and Arcturus' commitment to innovative vaccine technology for viral respiratory diseases.
Arcturus Therapeutics (Nasdaq: ARCT) has received FDA clearance for its Investigational New Drug (IND) application for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis (CF). This clearance allows Arcturus to initiate a Phase 2 multiple ascending dose study to evaluate the safety, tolerability, and efficacy of ARCT-032 in CF patients. The study will focus on individuals who do not qualify for or benefit from CFTR modulator therapy.
Dr. Juergen Froehlich, Chief Medical Officer of Arcturus, stated that this development provides an opportunity to further validate their LUNAR® technology for delivering mRNA via inhalation. The study will assess ARCT-032 administered over several weeks at multiple dose levels in CF patients.
Arcturus Therapeutics Holdings Inc. (ARCT), a global mRNA medicines company, has announced its participation in several upcoming investor and scientific conferences in September 2024. These include:
- Wells Fargo 2024 Healthcare Conference (Fireside Chat) on September 4
- RNA Leaders USA Conference (Presentation) on September 5
- H.C. Wainwright 26th Annual Global Investment Conference (Presentation) on September 9
- Cantor Fitzgerald Annual Healthcare Conference (Fireside Chat) on September 18
Arcturus focuses on developing infectious disease vaccines and addressing unmet medical needs in liver and respiratory rare diseases. Investors can access webcast links for these events through the Investor Relations/Events section of the company's website.
Arcturus Therapeutics (ARCT) announced its Q2 2024 financial results and pipeline progress. Key highlights include:
1. IND submitted for Phase 2 trial of ARCT-032 for cystic fibrosis
2. ARCT-810 (OTC deficiency) Phase 2 interim data expected in Q4
3. Kostaive® on track for Q4 commercial launch in Japan
4. Q2 revenue of $49.9 million, up from $10.5 million in Q2 2023
5. Net loss of $17.2 million ($0.64 per share) compared to $52.6 million ($1.98 per share) in Q2 2023
6. Cash position of $317.2 million as of June 30, 2024
The company's pipeline progress and financial results demonstrate continued advancement in mRNA therapeutics and a strengthened financial position.
Arcturus Therapeutics Holdings (Nasdaq: ARCT), a global mRNA medicines company, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for Tuesday, August 13, 2024, at 9:30 am Eastern Time in Boston. Arcturus specializes in developing infectious disease vaccines and treatments for liver and respiratory rare diseases.
Investors and interested parties can access a webcast and replay of Arcturus' presentation through the company's website. The presentation will be available in the 'Investor Relations/Events' section at https://ir.arcturusrx.com/investor-calendar. This conference appearance provides an opportunity for Arcturus to showcase its progress and potential to a wider audience of growth-oriented investors.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a global mRNA medicines company, has announced it will release its financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company will also host a conference call and webcast at 4:30 pm Eastern Time on the same day to discuss the results.
Arcturus focuses on developing infectious disease vaccines and medicines for liver and respiratory rare diseases. Investors and interested parties can join the earnings call using the provided domestic and international phone numbers or access the webcast through the company's website.
FAQ
What is the current stock price of Arcturus Therapeutics Holdings (ARCT)?
What is the market cap of Arcturus Therapeutics Holdings (ARCT)?
What does Arcturus Therapeutics specialize in?
What are the core technologies of Arcturus Therapeutics?
What kind of diseases is Arcturus targeting with its therapies?
What recent collaborations has Arcturus entered into?
What is Kostaive®?
Who are Arcturus' major partners?
What is LUNAR-OTC?
How extensive is Arcturus' patent portfolio?
Where is Arcturus Therapeutics headquartered?
How can I get more information about Arcturus Therapeutics?
